aged 18-70 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma
Eastern Cooperative Oncology Group performance status of 0 to 1
life expectancy of ≥ 3 months
patients who had failed first-line treatment with either XELOX (capecitabine combined with oxaliplatin) or FOLFOX (5-fluorouracil/leucovorin with oxaliplatin)
at least one measurable disease lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria
have adequate bone marrow, hepatic, and renal function
You may not be if
patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction
